Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai, Taisho Of Japan To Seek Osteo Drug Approval By Year's End

This article was originally published in PharmAsia News

Executive Summary

Japan's Chugai Pharmaceutical and Taisho Pharmaceutical, joint developers of an osteoporosis drug, plan to apply for approval in Japan by the end of this year. The companies made the decision based on Phase III trials that returned positive results. Chugai created the drug that helps promote absorption of calcium and bone formation, and Taisho helped it take the drug through trials that compared it with existing drugs. The two firms have other osteoporosis drugs in joint development. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts